A carregar...
miR-524-5p reduces the progression of the BRAF inhibitor-resistant melanoma
BRAF inhibitors were approved for the treatment of BRAF-mutant melanoma. However, most patients acquire the resistance to BRAF inhibitors after several months of treatment. miR-524-5p is considered as a tumor suppressor in many cancers, including melanoma. In this study, we investigated the biologic...
Na minha lista:
| Publicado no: | Neoplasia |
|---|---|
| Main Authors: | , , , , , , , , , , , , , , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
Neoplasia Press
2020
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7642759/ https://ncbi.nlm.nih.gov/pubmed/33142243 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.neo.2020.10.009 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|